Effects of Antidiabetic Drugs on Gut Microbiota Composition
Open accessThe DOI matches its Crossref record; 82 of the 85 references it cites were found in a registry or an index.
Abstract
Gut microbiota forms a catalog of about 1000 bacterial species; which mainly belong to the Firmicutes and Bacteroidetes phyla. Microbial genes are essential for key metabolic processes; such as the biosynthesis of short-chain fatty acids (SCFA); amino acids; bile acids or vitamins. It is becoming clear that gut microbiota is playing a prevalent role in pathologies such as metabolic syndrome; type 2 diabetes (T2D); inflammatory and bowel diseases. Obesity and related diseases; notably type 2 diabetes, induce gut dysbiosis. In this review; we aim to cover the current knowledge about the effects of antidiabetic drugs on gut microbiota diversity and composition as well as the potential beneficial effects mediated by specific taxa. Metformin is the first-line treatment against T2D. In addition to its glucose-lowering and insulin sensitizing effects, metformin promotes SCFA-producing and mucin-degrading bacteria. Other antidiabetic drugs discussed in this review show positive effects on dysbiosis; but without any consensus specifically regarding the Firmicutes to Bacteroidetes ratio. Thus, beneficial effects might be mediated by specific taxa.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In particular, the most studied medication is metformin, which seems to positively influence microbiota diversity and composition [61].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [61]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A human gut microbial gene catalogue established by metagenomic sequencing
MetaHIT Consortium, Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., et al. (2010) · Nature · doi:10.1038/nature08821 · Cited by 11,624 · cited 5×
“High-fat diet promotes taxa belonging to the Firmicutes (Clostridium ramosum) and Proteobacteria (Bilophila wadsworthia), while high-fiber diet increases the abundance in Bacteroidetes (Prevotella, Xylanibactera), Verrucomicrobia (Akkermansia muciniphila) and Actinobacteria (Bifidobacterium spp.) and decreases the amo…”
BackgroundInfluentialDiet rapidly and reproducibly alters the human gut microbiome
David, L. A., Maurice, C. F., Carmody, R. N., Gootenberg, D. B., Button, J. E., Wolfe, B. E., Ling, A. V., Devlin, A. S., Varma, Y., Fischbach, M. A., et al. (2014) · Nature · doi:10.1038/nature12820 · Cited by 10,100 · cited 1×
“Gut microbiota composition and diversity is predominantly influenced by the diet [6,34,42].”
BackgroundHuman gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
Diversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913 · cited 2×
“They are modulated by the diet, host health, age, ethnicity and genetics and thus are unique and highly variable among individuals [2,3].”
BackgroundA core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823 · cited 1×
“Nevertheless, Turnbaugh and colleagues [4] suggest that there is a “core gut microbiome” (i.”
BackgroundHuman gut microbiome viewed across age and geography
Yatsunenko, T., Rey, F. E., Manary, M. J., Trehan, I., Dominguez-Bello, M. G., Contreras, M., Magris, M., Hidalgo, G., Baldassano, R. N., Anokhin, A. P., et al. (2012) · Nature · doi:10.1038/nature11053 · Cited by 7,815 · cited 2×
“They are modulated by the diet, host health, age, ethnicity and genetics and thus are unique and highly variable among individuals [2,3].”
BackgroundEckel, R. H., Alberti, K., Grundy, S. M., & Zimmet, P. Z. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61794-3 · Cited by 6,295
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176
De Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 6×
“Whereas Escherichia probably plays an important role in the side-effects of metformin [19], Bifidobacterium adolescentis has been shown to negatively correlate to HbA1c.”
BackgroundInfluentialEckel, R. H., Grundy, S. M., & Zimmet, P. Z. (2005) · The Lancet · doi:10.1016/s0140-6736(05)66378-7 · Cited by 5,550
Functional interactions between the gut microbiota and host metabolism
Tremaroli, V., & Bäckhed, F. (2012) · Nature · doi:10.1038/nature11552 · Cited by 4,387
Drucker, D. J., & Nauck, M. A. (2006) · The Lancet · doi:10.1016/s0140-6736(06)69705-5 · Cited by 3,896 · cited 1×
“As such, in the past decade they have become a major target to treat T2D and related metabolic disorders [59,60].”
BackgroundFormation of short chain fatty acids by the gut microbiota and their impact on human metabolism
Morrison, D. J., & Preston, T. (2016) · Gut Microbes · doi:10.1080/19490976.2015.1134082 · Cited by 3,781 · cited 2×
“These carbohydrates are mostly catabolized into acetate, propionate and butyrate, but also lactate [73,74].”
BackgroundGut metagenome in European women with normal, impaired and diabetic glucose control
Karlsson, F. H., Tremaroli, V., Nookaew, I., Bergström, G., Behre, C. J., Fagerberg, B., Nielsen, J., & Bäckhed, F. (2013) · Nature · doi:10.1038/nature12198 · Cited by 3,115 · cited 1×
“[41] developed a model based on gut metagenome profiles to diagnose T2D in human patients, but also to identify individuals with a high risk of developing T2D.”
BackgroundThe Effect of Diet on the Human Gut Microbiome: A Metagenomic Analysis in Humanized Gnotobiotic Mice
Turnbaugh, P. J., Ridaura, V. K., Faith, J. J., Rey, F. E., Knight, R., & Gordon, J. I. (2009) · Science Translational Medicine · doi:10.1126/scitranslmed.3000322 · Cited by 3,058 · cited 1×
“Moreover, energy-rich diets can alter gut microbiota composition in a single day [39].”
BackgroundEnergy contributions of volatile fatty acids from the gastrointestinal tract in various species
Bergman, E. N. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.2.567 · Cited by 2,750 · cited 1×
“2 to 10% of human energy requirements [78,79].”
BackgroundReview article: the role of butyrate on colonic function
HAMER, H. M., JONKERS, D., VENEMA, K., VANHOUTVIN, S., TROOST, F. J., & BRUMMER, R. ‐. (2008) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03562.x · Cited by 2,721 · cited 1×
“It was also proposed to improve colonic barrier function and promote satiety [80].”
BackgroundTolhurst, G., Heffron, H., Lam, Y. S., Parker, H. E., Habib, A. M., Diakogiannaki, E., Cameron, J., Grosse, J., Reimann, F., & Gribble, F. M. (2012) · Diabetes · doi:10.2337/db11-1019 · Cited by 2,404 · cited 1×
“Acetate and propionate are able to stimulate GLP-1 secretion in primary murine colonic cultures via the G-protein-coupled free fatty acid receptor (FFAR)2 and FFAR3 [64].”
BackgroundThe biology of incretin hormones
Drucker, D. J. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.01.004 · Cited by 2,210 · cited 1×
“GIP and GLP-1 are secreted by the gut within minutes after food ingestion by intestinal K and L cells respectively [61].”
BackgroundDisentangling type 2 diabetes and metformin treatment signatures in the human gut microbiota
MetaHIT consortium, Forslund, K., Hildebrand, F., Nielsen, T., Falony, G., Le Chatelier, E., Sunagawa, S., Prifti, E., Vieira-Silva, S., Gudmundsdottir, V., et al. (2015) · Nature · doi:10.1038/nature15766 · Cited by 2,116
Akkermansia muciniphila gen. nov., sp. nov., a human intestinal mucin-degrading bacterium
Derrien, M., Vaughan, E. E., Plugge, C. M., & de Vos, W. M. (2004) · International Journal of Systematic and Evolutionary Microbiology · doi:10.1099/ijs.0.02873-0 · Cited by 2,094 · cited 1×
“Propionate production is dominated by a few bacterial genera with Akkermansia municiphila as a key producer [75].”
BackgroundRegulation of short-chain fatty acid production
Macfarlane, S., & Macfarlane, G. T. (2003) · Proceedings of the Nutrition Society · doi:10.1079/pns2002207 · Cited by 1,939 · cited 1×
“These carbohydrates are mostly catabolized into acetate, propionate and butyrate, but also lactate [73,74].”
BackgroundCellular and molecular mechanisms of metformin: an overview
Viollet, B., Guigas, B., Garcia, N. S., Leclerc, J., Foretz, M., & Andreelli, F. (2012) · Clinical Science · doi:10.1042/cs20110386 · Cited by 1,720 · cited 11×
“GLP-1 Receptor Agonists GLP-1 RA are modified peptides sharing homology with GLP-1 [65].”
BackgroundInfluentialWu, H., Esteve, E., Tremaroli, V., Khan, M. T., Caesar, R., Mannerås-Holm, L., Ståhlman, M., Olsson, L. M., Serino, M., Planas-Fèlix, M., et al. (2017) · Nature Medicine · doi:10.1038/nm.4345 · Cited by 1,632 · cited 6×
“adolescentis, which indicates that this drug may be a growth factor for some bacterial species [20,26].”
BackgroundInfluentialShin, N.-R., Lee, J.-C., Lee, H.-Y., Kim, M.-S., Whon, T. W., Lee, M.-S., & Bae, J.-W. (2014) · Gut · doi:10.1136/gutjnl-2012-303839 · Cited by 1,550 · cited 4×
“Furthermore, some beneficial actions, but also side-effects of metformin are thought to be mediated by gut microbiota [19,25,52].”
BackgroundInfluentialImpact of the gut microbiota on inflammation, obesity, and metabolic disease
Boulangé, C. L., Neves, A. L., Chilloux, J., Nicholson, J. K., & Dumas, M.-E. (2016) · Genome Medicine · doi:10.1186/s13073-016-0303-2 · Cited by 1,438 · cited 2×
“and morbidity in industrialized countries because it increases the risk of developing type 2 diabetes (T2D) or cardiovascular diseases [12,14,15].”
BackgroundMetformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,349 · cited 12×
“GLP-1 Receptor Agonists GLP-1 RA are modified peptides sharing homology with GLP-1 [65].”
BackgroundInfluentialHow informative is the mouse for human gut microbiota research?
Nguyen, T. L. A., Vieira-Silva, S., Liston, A., & Raes, J. (2015) · Disease Models & Mechanisms · doi:10.1242/dmm.017400 · Cited by 1,334
Bile acids and the gut microbiome
Ridlon, J. M., Kang, D. J., Hylemon, P. B., & Bajaj, J. S. (2014) · Current Opinion in Gastroenterology · doi:10.1097/mog.0000000000000057 · Cited by 1,329
Grundy, S. M. (2011) · Atlas of Atherosclerosis and Metabolic Syndrome · doi:10.1007/978-1-4419-5839-6_1 · Cited by 1,223
Minireview: Gut microbiota: The neglected endocrine organ
Clarke, G., Stilling, R. M., Kennedy, P. J., Stanton, C., Cryan, J. F., & Dinan, T. G. (2014) · Molecular Endocrinology · doi:10.1210/me.2014-1108 · Cited by 1,192 · cited 1×
“The gut microbiota refers to the trillions of microbes living in our guts and can be considered a separate endocrine organ [1].”
BackgroundZhang, C., Zhang, M., Wang, S., Han, R., Cao, Y., Hua, W., Mao, Y., Zhang, X., Pang, X., Wei, C., et al. (2010) · The ISME Journal · doi:10.1038/ismej.2009.112 · Cited by 1,024
The role of the gut microbiota in energy metabolism and metabolic disease
Cani, P., & Delzenne, N. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209788168164 · Cited by 974 · cited 1×
“Because of the interactions between gut microbiota and host physiology, it is becoming evident that the gut and its associated bacteria play a prevalent role in diseases and especially in metabolic syndrome [6,11,12].”
BackgroundVilsboll, T., Christensen, M., Junker, A. E., Knop, F. K., & Gluud, L. L. (2012) · BMJ · doi:10.1136/bmj.d7771 · Cited by 970 · cited 1×
“Similarly to other GLP-1 RA, liraglutide is known to induce weight loss [66].”
BackgroundMetformin retards aging in C. elegans by altering microbial folate and methionine metabolism
Cabreiro, F., Au, C., Leung, K.-Y., Vergara-Irigaray, N., Cochemé, H. M., Noori, T., Weinkove, D., Schuster, E., Greene, N. D. E., & Gems, D. (2013) · Cell · doi:10.1016/j.cell.2013.02.035 · Cited by 967 · cited 2×
“coli in vitro and rather shows antibiotic effects [20,53].”
BackgroundHuman Gut Microbiota Changes Reveal the Progression of Glucose Intolerance
Zhang, X., Shen, D., Fang, Z., Jie, Z., Qiu, X., Zhang, C., Chen, Y., & Ji, L. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071108 · Cited by 946 · cited 1×
“Likewise, T2D induces a dysbiosis, characterized by a decrease in the butyrate-producing bacteria abundance [19,30] and in Akkermansia muciniphila, which was further proposed to be a biomarker for glucose intolerance [40].”
BackgroundMurphy, E. F., Cotter, P. D., Healy, S., Marques, T. M., O'Sullivan, O., Fouhy, F., Clarke, S. F., O'Toole, P. W., Quigley, E. M., Stanton, C., et al. (2010) · Gut · doi:10.1136/gut.2010.215665 · Cited by 946
Louis, P., Young, P., Holtrop, G., & Flint, H. J. (2010) · Environmental Microbiology · doi:10.1111/j.1462-2920.2009.02066.x · Cited by 774 · cited 2×
“They are involved in multiple processes; they regulate gene expression and can stimulate gut peptide production [76,77].”
BackgroundPPARs: therapeutic targets for metabolic disease
Berger, J. P., Akiyama, T. E., & Meinke, P. T. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.03.003 · Cited by 713 · cited 1×
“They decrease insulin resistance in adipose tissue, liver and skeletal muscle [68].”
Backgroundde la Cuesta-Zuluaga, J., Mueller, N. T., Corrales-Agudelo, V., Velásquez-Mejía, E. P., Carmona, J. A., Abad, J. M., & Escobar, J. S. (2017) · Diabetes Care · doi:10.2337/dc16-1324 · Cited by 704 · cited 1×
“Firmicutes to Bacteroidetes ↓a [16] ↓a [17] ↑a [18] ↑a [18] SCFA-producing bacteria ↑h [19–21], a [22] ↑h [23,24] ↑↓a [17] Firmicutes ↓a [17] ↑a [18] ↓↑a [18] Clostridiales (order) ↑h [24] ↓a [18] Anaerostipes ↑a [18] Anaerotruncus ↓a [25] Blautia ↑a [22]↓a [25] ↓a [17] ↑a [18] Butyricicoccus ↑a [22] ↓h [24] Butyrivib…”
Exercise Modifies the Gut Microbiota with Positive Health Effects
Monda, V., Villano, I., Messina, A., Valenzano, A., Esposito, T., Moscatelli, F., Viggiano, A., Cibelli, G., Chieffi, S., Monda, M., et al. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3831972 · Cited by 654 · cited 1×
“On the other hand, physical activity modifies gut physiology and morphology in addition to gut microbiota composition [45].”
BackgroundZhang, X., Zhao, Y., Xu, J., Xue, Z., Zhang, M., Pang, X., Zhang, X., & Zhao, L. (2015) · Scientific Reports · doi:10.1038/srep14405 · Cited by 630 · cited 1×
“Firmicutes to Bacteroidetes ↓a [16] ↓a [17] ↑a [18] ↑a [18] SCFA-producing bacteria ↑h [19–21], a [22] ↑h [23,24] ↑↓a [17] Firmicutes ↓a [17] ↑a [18] ↓↑a [18] Clostridiales (order) ↑h [24] ↓a [18] Anaerostipes ↑a [18] Anaerotruncus ↓a [25] Blautia ↑a [22]↓a [25] ↓a [17] ↑a [18] Butyricicoccus ↑a [22] ↓h [24] Butyrivib…”
Evans, C. C., LePard, K. J., Kwak, J. W., Stancukas, M. C., Laskowski, S., Dougherty, J., Moulton, L., Glawe, A., Wang, Y., Leone, V., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0092193 · Cited by 587 · cited 2×
“Studies in rodents have shown that voluntary exercise leads to an increase in n-butyrate caecal concentration and that the Firmicutes to Bacteroidetes ratio decreases proportionally to the total distance run [46,47].”
BackgroundInteraction of gut microbiota with bile acid metabolism and its influence on disease states
Staley, C., Weingarden, A. R., Khoruts, A., & Sadowsky, M. J. (2017) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-016-8006-6 · Cited by 581
Interactions between gut bacteria and bile in health and disease
Long, S. L., Gahan, C. G. M., & Joyce, S. A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2017.06.002 · Cited by 495
The role of Gut Microbiota in the development of obesity and Diabetes
Baothman, O. A., Zamzami, M. A., Taher, I., Abubaker, J., & Abu-Farha, M. (2016) · Lipids in Health and Disease · doi:10.1186/s12944-016-0278-4 · Cited by 493 · cited 1×
“Gut microbiota composition and diversity is predominantly influenced by the diet [6,34,42].”
BackgroundRecent developments and biological activities of thiazolidinone derivatives: A review
Jain, A. K., Vaidya, A., Ravichandran, V., Kashaw, S. K., & Agrawal, R. K. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.03.069 · Cited by 461 · cited 1×
“In addition to their antidiabetic properties, thiazolidinediones can have multiples effects such as anti-tumoral, anti-inflammatory, anti-bacterial or anti-fungal [69] and may indirectly affect gut bacteria.”
BackgroundEffect of Metformin on Metabolic Improvement and Gut Microbiota
Lee, H., & Ko, G. (2014) · Applied and Environmental Microbiology · doi:10.1128/aem.01357-14 · Cited by 385 · cited 4×
“adolescentis, which indicates that this drug may be a growth factor for some bacterial species [20,26].”
BackgroundInfluentialBrunkwall, L., & Orho-Melander, M. (2017) · Diabetologia · doi:10.1007/s00125-017-4278-3 · Cited by 355
MATSUMOTO, M., INOUE, R., TSUKAHARA, T., USHIDA, K., CHIJI, H., MATSUBARA, N., & HARA, H. (2008) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.70474 · Cited by 352 · cited 1×
“Studies in rodents have shown that voluntary exercise leads to an increase in n-butyrate caecal concentration and that the Firmicutes to Bacteroidetes ratio decreases proportionally to the total distance run [46,47].”
BackgroundMetabolic syndrome and nonalcoholic fatty liver disease: Is insulin resistance the link?
Asrih, M., & Jornayvaz, F. R. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.02.018 · Cited by 330 · cited 1×
“and morbidity in industrialized countries because it increases the risk of developing type 2 diabetes (T2D) or cardiovascular diseases [12,14,15].”
BackgroundSelf-citationThe gut microbiota and metabolic disease: current understanding and future perspectives
Arora, T., & Bäckhed, F. (2016) · Journal of Internal Medicine · doi:10.1111/joim.12508 · Cited by 303 · cited 1×
“Obesity also contributes to a reduction of microbial diversity [31].”
BackgroundGlucagon-like peptide 1 undergoes differential tissue-specific metabolism in the anesthetized pig
Deacon, C. F., Pridal, L., Klarskov, L., Olesen, M., & Holst, J. J. (1996) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.1996.271.3.e458 · Cited by 299 · cited 1×
“In addition to enzymes, incretin metabolites are cleared by renal filtration, thus endogenous half-life of these peptides is very short [63].”
BackgroundThe Intestinal Microbiota in Metabolic Disease
Woting, A., & Blaut, M. (2016) · Nutrients · doi:10.3390/nu8040202 · Cited by 284
Novel Gut-Based Pharmacology of Metformin in Patients with Type 2 Diabetes Mellitus
Napolitano, A., Miller, S., Nicholls, A. W., Baker, D., Van Horn, S., Thomas, E., Rajpal, D., Spivak, A., Brown, J. R., & Nunez, D. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0100778 · Cited by 282 · cited 2×
“Furthermore, some beneficial actions, but also side-effects of metformin are thought to be mediated by gut microbiota [19,25,52].”
BackgroundEverard, A., & Cani, P. D. (2014) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-014-9288-6 · Cited by 261 · cited 2×
“They are involved in multiple processes; they regulate gene expression and can stimulate gut peptide production [76,77].”
BackgroundAraújo, J. R., Tomas, J., Brenner, C., & Sansonetti, P. J. (2017) · Biochimie · doi:10.1016/j.biochi.2017.05.019 · Cited by 261
Krych, L., Hansen, C. H. F., Hansen, A. K., van den Berg, F. W. J., & Nielsen, D. S. (2013) · PLoS ONE · doi:10.1371/journal.pone.0062578 · Cited by 249 · cited 2×
“), but the strain/population will also influence the results [2,70].”
BackgroundGut microbiota and energy balance: role in obesity
Blaut, M. (2015) · Proceedings of The Nutrition Society · doi:10.1017/s0029665114001700 · Cited by 232 · cited 1×
“2 to 10% of human energy requirements [78,79].”
BackgroundBiotechnology and molecular biology of the ?-glucosidase inhibitor acarbose
Wehmeier, U. F., & Piepersberg, W. (2004) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-003-1477-2 · Cited by 213
Zhang, X., Fang, Z., Zhang, C., Xia, H., Jie, Z., Han, X., Chen, Y., & Ji, L. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0226-y · Cited by 184 · cited 7×
“Whereas Escherichia probably plays an important role in the side-effects of metformin [19], Bifidobacterium adolescentis has been shown to negatively correlate to HbA1c.”
BackgroundInfluentialGut Microbiota, Low-grade Inflammation, and Metabolic Syndrome
Chassaing, B., & Gewirtz, A. T. (2014) · Toxicologic Pathology · doi:10.1177/0192623313508481 · Cited by 172 · cited 1×
“Albeit, the side effect of gut microbiota is the induction of low-grade inflammation, mainly through the innate immune system and the pattern recognition receptors (PRRs) [10].”
BackgroundHuman intestinal microbiota: Characterization of a simplified and stable gnotobiotic rat model
Becker, N., Kunath, J., Loh, G., & Blaut, M. (2011) · Gut Microbes · doi:10.4161/gmic.2.1.14651 · Cited by 170 · cited 1×
“Note that similarly to comparisons made at the phylum level, the SCFA-producing bacteria “label” could be misleading as these bacteria are broadly distributed and might compete with each other [72].”
ResultWang, L., Li, P., Tang, Z., Yan, X., & Feng, B. (2016) · Scientific Reports · doi:10.1038/srep33251 · Cited by 165 · cited 1×
“Firmicutes to Bacteroidetes ↓a [16] ↓a [17] ↑a [18] ↑a [18] SCFA-producing bacteria ↑h [19–21], a [22] ↑h [23,24] ↑↓a [17] Firmicutes ↓a [17] ↑a [18] ↓↑a [18] Clostridiales (order) ↑h [24] ↓a [18] Anaerostipes ↑a [18] Anaerotruncus ↓a [25] Blautia ↑a [22]↓a [25] ↓a [17] ↑a [18] Butyricicoccus ↑a [22] ↓h [24] Butyrivib…”
Su, B., Liu, H., Li, J., Sunli, Y., Liu, B., Liu, D., Zhang, P., & Meng, X. (2015) · Journal of Diabetes · doi:10.1111/1753-0407.12232 · Cited by 137 · cited 7×
“Whereas Escherichia probably plays an important role in the side-effects of metformin [19], Bifidobacterium adolescentis has been shown to negatively correlate to HbA1c.”
BackgroundInfluentialJornayvaz, F. R., Samuel, V. T., & Shulman, G. I. (2010) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.012809.104726 · Cited by 126 · cited 1×
“The metabolic syndrome combines multiple disorders including insulin resistance, dyslipidemia, hyperglycemia, hypertension and central obesity [13].”
BackgroundSelf-citationBai, J., Zhu, Y. G., & Dong, Y. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.10.043 · Cited by 124 · cited 3×
“On the other hand, pioglitazone exacerbates the drop in IL-10 level and the authors did not observe any significant decline in the endotoxin-producing families Enterobacteriaceae and Desulfovibrionaceae [28].”
BackgroundAcarbose Enhances Human Colonic Butyrate Production
Weaver, G. A., Tangel, C. T., Krause, J. A., Parfitt, M. M., Jenkins, P., Rader, J. M., LEWIS, B. A., Miller, T. L., & Wolin, M. J. (1997) · Journal of Nutrition · doi:10.1093/jn/127.5.717 · Cited by 110 · cited 1×
“This suggests that acarbose prevents starch processing and absorption and enhances starch-fermenting and butyrate-producing bacteria, at the same time, it inhibits starch use by propionate-producing bacteria [58].”
BackgroundYan, X., Feng, B., Li, P., Tang, Z., & Wang, L. (2016) · Journal of Diabetes Research · doi:10.1155/2016/2093171 · Cited by 110 · cited 3×
“After treatment, diabetic rat stools are enriched in Roseburia and depleted in Blautia, while the relative abundance of Clostridium do not change [17].”
BackgroundMechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP
Mentlein, R. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2009.03.005 · Cited by 94 · cited 1×
“Both incretins are mainly inactivated by the enzyme dipeptidyl peptidase-4 (DPP-4) and endogenously co-occur as an active and an inactive form [62].”
BackgroundBonora, E., Cigolini, M., Bosello, O., Zancanaro, C., Capretti, L., Zavaroni, I., Coscelli, C., & Butturini, U. (1984) · Current Medical Research and Opinion · doi:10.1185/03007998409109558 · Cited by 85 · cited 1×
“Interestingly, intravenous administration of metformin does not improve glycaemia [51].”
BackgroundMedical Management of Diabesity: Do We Have Realistic Targets?
Pappachan, J. M., & Viswanath, A. (2017) · Current Diabetes Reports · doi:10.1007/s11892-017-0828-9 · Cited by 80 · cited 1×
“Amongst biguanides, metformin is currently used as first-line treatment of T2D for its glucose lowering and insulin sensitizing effects [48,49].”
BackgroundBrunkhorst, C., Andersen, C., & Schneider, E. (1999) · Journal of Bacteriology · doi:10.1128/jb.181.8.2612-2619.1999 · Cited by 41
Kishida, Y., Okubo, H., Ohno, H., Oki, K., & Yoneda, M. (2017) · Journal of Gastroenterology · doi:10.1007/s00535-017-1331-4 · Cited by 34 · cited 3×
“Firmicutes to Bacteroidetes ↓a [16] ↓a [17] ↑a [18] ↑a [18] SCFA-producing bacteria ↑h [19–21], a [22] ↑h [23,24] ↑↓a [17] Firmicutes ↓a [17] ↑a [18] ↓↑a [18] Clostridiales (order) ↑h [24] ↓a [18] Anaerostipes ↑a [18] Anaerotruncus ↓a [25] Blautia ↑a [22]↓a [25] ↓a [17] ↑a [18] Butyricicoccus ↑a [22] ↓h [24] Butyrivib…”
BackgroundHuo, T., Xiong, Z., Lu, X., & Cai, S. (2014) · Biomedical Chromatography · doi:10.1002/bmc.3247 · Cited by 33 · cited 1×
“[67] suggested that sulfonylureas have a beneficial effect on gut metabolism of T2D patients based on their urine levels of hippurate, phenylalanine and tryptophane.”
BackgroundIncretin Therapy – Present and Future
Garber, A. J. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.307 · Cited by 31
Ju, H., Lee, Y. S., Ha, M. J., Cho, Y., Yi, H., Hwang, Y.-J., Hwang, G., & Shin, M. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej15-0747 · Cited by 28 · cited 1×
“Firmicutes to Bacteroidetes ↓a [16] ↓a [17] ↑a [18] ↑a [18] SCFA-producing bacteria ↑h [19–21], a [22] ↑h [23,24] ↑↓a [17] Firmicutes ↓a [17] ↑a [18] ↓↑a [18] Clostridiales (order) ↑h [24] ↓a [18] Anaerostipes ↑a [18] Anaerotruncus ↓a [25] Blautia ↑a [22]↓a [25] ↓a [17] ↑a [18] Butyricicoccus ↑a [22] ↓h [24] Butyrivib…”
Effects of alpha-glucosidase inhibitors on mouth to caecum transit time in humans.
Ladas, S. D., Frydas, A., Papadopoulos, A. A., & Raptis, S. A. (1992) · Gut · doi:10.1136/gut.33.9.1246 · Cited by 27
Maruhama, Y., Nagasaki, A., Kanazawa, Y., Hirakawa, H., Gotō, Y., Nishiyama, H., KISHIMOTO, Y., & Shimoyama, T. (1980) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.132.453 · Cited by 26 · cited 8×
“Whereas Escherichia probably plays an important role in the side-effects of metformin [19], Bifidobacterium adolescentis has been shown to negatively correlate to HbA1c.”
BackgroundInfluentialA Structural Basis for Biguanide Activity
Gabel, S. A., Duff, M. R., Pedersen, L. C., DeRose, E. F., Krahn, J. M., Howell, E. E., & London, R. E. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00619 · Cited by 24 · cited 1×
“It has notably been shown that metformin impairs folate metabolism in Escherichia coli [53], possibly by the inhibition of the dihydrofolate reductase activity [54].”
BackgroundGlucagon-like peptide-1 receptors agonists (GLP1 RA).
Kalra, S. (2013) · PubMed · Cited by 9
The Gut Impacts Diabetic Management Tomorrow: The Recent Messages from Intestine and Microbiota
Fukui, H. (2016) · Journal of Clinical Nutrition & Dietetics · doi:10.4172/2472-1921.100027 · Cited by 5
Cited by
Yuan, T., Yang, T., Chen, H., Fu, D., Hu, Y., Wang, J., Yuan, Q., Yu, H., Xu, W., & Xie, X. (2019) · Redox Biology · doi:10.1016/j.redox.2018.09.025 · Cited by 743
“The abundance of the gut microbiota also improves with metformin treatment in humans [189].”
BackgroundArmanini, D., Boscaro, M., Bordin, L., & Sabbadin, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23084110 · Cited by 324
Gut microbiota influence in type 2 diabetes mellitus (T2DM)
Cunningham, A. L., Stephens, J. W., & Harris, D. A. (2021) · Gut Pathogens · doi:10.1186/s13099-021-00446-0 · Cited by 270
Obesity in Type 1 Diabetes: Pathophysiology, Clinical Impact, and Mechanisms
Corbin, K. D., Driscoll, K. A., Pratley, R. E., Smith, S. R., Maahs, D. M., Mayer-Davis, E. J., & Advancing Care for Type 1 Diabetes and Obesity Network (ACT1ON) (2018) · Endocrine Reviews · doi:10.1210/er.2017-00191 · Cited by 262
Salguero, M., Al‑Obaide, M., Singh, R., Siepmann, T., & Vasylyeva, T. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7943 · Cited by 257
“Metformin, a blood glucose regulator, was reported to increase the relative abundance of LPS-producing Gram-negative gut bacteria (22).”
Metadata
- Authors
- Montandon, S., & Jornayvaz, F.
- Affiliations
- University Hospital of Geneva (CH)
- Corresponding author
- Jornayvaz, François
- ORCID
- Jornayvaz, François
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2017-09-30
- Volume
- 8
- Issue
- 10
- Pages
- 250
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC5664100
- OpenAlex
- W2756853277
- Cited by
- 135
- References
- 85
- Citations by year
- 2025: 17 · 2024: 14 · 2023: 20 · 2022: 16 · 2021: 17 · 2020: 20 · 2019: 16 · 2018: 14 · 2017: 1
- FWCI
- 1.31
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Archive ouverte UNIGE (University of Geneva) (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Archive ouverte UNIGE (University of Geneva) (submittedVersion, cc-by)
- Funders
- Novo Nordisk
- Gottfried und Julia Bangerter-Rhyner-Stiftung
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, antidiabetic drugs, type 2 diabetes, metformin, short-chain fatty acids, gut dysbiosis, Firmicutes/Bacteroidetes ratio, mucin-degrading bacteria, obesity, microbial taxa, bile acids, insulin sensitivity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.